Catalyst shares dive amid speculation about ‘off-label’ rare disease rivalShares in Catalyst Pharmaceuticals have dived after the US regulator approved a potential competitor to its rare disease Share XCatalyst shares dive amid speculation about ‘off-label’ rare disease rivalhttps://pharmaphorum.com/news/catalyst-shares-dive-amid-speculation-about-off-label-rare-disease-rival/
Catalyst defends huge US price hike for rare disease drugCatalyst Pharmaceuticals has defended hiking the price of the rare disease drug Firdapse (amifampridine) from virtually nothing to Share XCatalyst defends huge US price hike for rare disease drughttps://pharmaphorum.com/news/catalyst-defends-huge-us-price-hike-for-rare-disease-drug/
Catalyst to re-submit rare disease drug after trial successAlready approved in EU, Catalyst aiming for FDA filing next year. Share XCatalyst to re-submit rare disease drug after trial successhttps://pharmaphorum.com/news/catalyst-us-filing-lems-drug/